Clinical trials: Acute Respiratory Infections
COVID-19, Coronavirus Disease 2019
Tigerase® Efficacy and Safety as Part of Complex Therapy in Patients With COVID-19
It is a multicenter, open-label, randomized, parallel-group study of the efficacy and safety of Tigerase® (GENERIUM JSC, Russia) with standard therapy versus standard therapy in patients with COVID-19.
- Trial name
- NCT04459325
- Testing
- Tigerase® and best available care, Best available care
- Where
- 6 sites in Russia
- Volunteers
- 100 people
- Sponsor
- AO GENERIUM
Acute Respiratory Infection
Efficacy and Safety of Polyoxidonium, Nasal and Sublingual Spray, 6 mg/ml in Children Aged 1-12 Years With ARI
The purpose of this study is is to demonstrate superiority of Polyoxidonium, nasal and sublingual spray, 6 mg/ml over placebo in children aged from 1 to 12 years with acute respiratory viral infections.
- Trial name
- NCT03840135
- Testing
- Polyoxidonium 6 mg/ml
- Where
- 11 sites in Russia
- Volunteers
- 172 people
- Sponsor
- NPO Petrovax
COVID-19
Study of the Efficacy and Safety of a Single Administration of Olokizumab vs. Placebo in Addition to Standard Treatment in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19).
The primary objective of the study is to evaluate the efficacy of a single dose of OKZ (64 mg) vs placebo in addition to standard therapy in patients with severe SARS-CoV-2 infection (COVID-19) at Day 29.
- Trial name
- NCT04452474
- Testing
- Olokizumab 64 mg
- Sponsor
- R-Pharm
Acute Rhinosinusitis, Recurrent Acute Rhinosinusitis
NAC Inhalation in the Treatment Of Symptomatic acuTe rhinosinUSitis
N-acetylcysteine (NAC), known to have mucolytic and antioxidant effects, is widely used to treat respiratory diseases and manage post-surgery pulmonary complications.
- Conditions
- Acute Rhinosinusitis, Recurrent Acute Rhinosinusitis, Chronic Rhinosinusitis
- Trial name
- NOTUS (NCT04131686)
- Where
- South Korea
- Volunteers
- 294 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Influenza, Human, Acute Respiratory Infection
Efficacy and Safety of Ingavirin®, Capsules, 60 mg, in Children With Influenza and Other Acute Respiratory Viral Infections
The study is planned to evaluate the therapeutic efficacy and safety of Ingavirin®, capsules, 60 mg, in the treatment of influenza or other acute respiratory infections in children from 13 to 17 years compared with placebo.
- Conditions
- Influenza, Human, Acute Respiratory Infection, Common Cold
- Trial name
- NCT06315400
- Testing
- Ingavirin®
- Where
- 3 sites in Russia
- Volunteers
- 80 people
- Sponsor
- Valenta Pharm JSC
Acute Respiratory Tract Infections
FebriDx DISRUPT Acute Respiratory Infection Trial in Acute Respiratory Infection: An Evaluation of FebriDx® POC Test
The aim of this study is to determine performance characteristics of the FebriDx test in predicting viral or bacterial infection etiology among febrile (observed or reported) patients presenting the emergency department, urgent…
- Trial name
- NCT02018198
- Testing
- FebriDx
- Where
- 20 sites in United States
- Volunteers
- 540 people, healthy volunteers welcome
- Sponsor
- Rapid Pathogen Screening
Sinusitis
Sinuclean's Treatment Of Sinusitis' Symptoms
The goal of the study is to demonstrate that SINUclean DM® spray, added to the standard (amoxicillin/clavulanate) therapy of the acute episode of sinusitis (acute, subacute or chronic), is safe ad capable to determine the…
- Trial name
- SToSS (NCT00747747)
- Testing
- Saline solution, Sinuclean DM Spray
- Where
- Italy
- Volunteers
- 49 people
- Sponsor
- Galsor S.r.l.
Acute Nasopharyngitis
Safety and Pharmacokinetic Study of Intranasal 2-DG in Healthy Volunteers
2-DG-01 is a randomized, double-blind, placebo-controlled, single and multiple ascending dose phase 1 study assessing safety, tolerability and pharmacokinetics of 2-DG in normal healthy volunteers (NHV).
- Trial name
- NCT05314933
- Testing
- 2-Deoxyglucose
- Where
- Austria
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- G.ST Antivirals GmbH
Pharyngitis
Testing The Effectiveness Of Celecoxib In Patients With Painful Sore Throat
We are proposing a study in which we utilize and augment the sore throat pain model to assess the analgesic effectiveness of celecoxib compared to placebo in patients with painful pharyngitis under randomized, double-blind…
- Trial name
- NCT00402987
- Testing
- Celecoxib
- Where
- United States
- Volunteers
- 269 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
COVID-19
A Study to Learn About Bivalent COVID-19 RNA Vaccine Candidate(s) in Healthy Infants and Children
The purpose of this clinical trial is to learn about the safety and immune responses of the study vaccine (called a bivalent BNT162b2 Omicron containing vaccine) in healthy infants and children.
- Trial name
- NCT05630352
- Testing
- Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 3 microgram dose, Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 6 microgram dose, Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 10 microgram dose
- Volunteers
- healthy volunteers welcome
- Sponsor
- BioNTech SE
COVID-19
A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection
The purpose of this clinical trial is to learn whether the study medicine prevent symptoms of COVID-19 in adults who have been exposed to household member(s) with a confirmed symptomatic COVID-19 infection.
- Trial name
- NCT05047601
- Testing
- PF-07321332, Ritonavir
- Where
- 170 sites in United States, Argentina and 15 more
- Volunteers
- 2,954 people
- Sponsor
- Pfizer
Multiple Myeloma
A Safety and Efficacy of Pomalyst® Capsules Under the Actual Use in All Patients Who Are Treated With Pomalyst at a Dose of 1 mg, 2 mg, 3 mg, or 4 mg
1. Planned enrollment period One year (The planned number of patients to be enrolled is set to 400 patients.) Since all patients who are prescribed with Pomalyst are registered in RevMate®, enrollment using the Registration Form…
- Trial name
- NCT02921828
- Where
- 2 sites in United States, Japan
- Volunteers
- 1,149 people
- Sponsor
- Celgene
Coronavirus Infection, Severe Acute Respiratory Infection
NA-831, Atazanavir and Dexamethasone Combination Therapy for the Treatment of COVID-19 Infection
This Phase 2/3 trial evaluates four treatment strategies for non-critically ill hospitalized participants (not requiring ICU admission and/or mechanical ventilation) with SARS CoV-2 infection, in which participants will receive…
- Conditions
- Coronavirus Infection, Severe Acute Respiratory Infection, Severe Acute Respiratory Syndrome Coronavirus 2
- Trial name
- NATADEX (NCT04452565)
- Testing
- Drug: NA-831, NA-831 and Atazanavir, NA-831and Dexamethasone
- Where
- 31 sites in United States
- Volunteers
- 525 people
- Sponsor
- Biomed Industries, Inc.
Long COVID
Prospective, Open-label Study of Seraph 100 in Patients With Prolonged COVID (PC)
This study will use a prospective, open, single-arm design, in which a group of 100 patients with a diagnosis of prolonged COVID, previously selected according to inclusion and exclusion criteria, and who have undergone informed…
- Trial name
- NCT06637800
- Testing
- Seraph® 100 Microbind® Affinity Blood Filter (Seraph 100)
- Where
- Mexico
- Sponsor
- ExThera Medical Corporation
Severe Acute Respiratory Syndrome (SARS) Pneumonia
Stem Cell Educator Therapy Treat the Viral Inflammation in COVID-19
Currently, the growing epidemic of a new coronavirus infectious disease (Covid-19) is wreaking havoc worldwide, which is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
- Trial name
- NCT04299152
- Testing
- Stem Cell Educator-Treated Mononuclear Cells Apheresis
- Volunteers
- 20 people
- Sponsor
- Throne Biotechnologies Inc.
Acute Respiratory Distress Syndrome
Pilot Clinical Study of NOA-001 for ARDS (Acute Respiratory Distress Syndrome)
The primary object of this clinical study is to investigate the efficacy and the safety of NOA-001 in patients with ARDS (ARDS caused by Non-COVID-19 or COVID-19).
- Trial name
- NCT04804943
- Testing
- NOA-001
- Where
- Japan
- Volunteers
- 45 people
- Sponsor
- Toray Industries, Inc
Corona Virus Infection, COVID-19
Inhaled NO for the Treatment of COVID-19 Caused by SARS-CoV-2 (US Trial)
The purpose of this open label, randomized, study is to obtain information on the safety and efficacy of 80 ppm Nitric Oxide given in addition to the standard of care of patients with COVID-19 caused by SARS-CoV-2.
- Conditions
- Corona Virus Infection, COVID-19, SARS-CoV 2, Nitric Oxide
- Trial name
- NCT04397692
- Testing
- Nitric Oxide delivered via LungFit™ system
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Beyond Air Inc.
Influenza
To Assess the Efficacy of GP681 Tablet Versus Placebo in Patients With Acute Uncomplicated Influenza Virus Infection
This study will evaluate the efficacy, safety, and population pharmacokinetics of a single, oral dose of GP681 compared with placebo in patients aged 12 to 65 years with acute uncomplicated influenza virus infection
- Trial name
- NCT05474755
- Testing
- GP681 40mg
- Where
- China
- Volunteers
- 591 people
- Sponsor
- Jiangxi Qingfeng Pharmaceutical Co. Ltd.
Acute Respiratory Viral Infections
Clinical Trial of Efficacy and Safety of Ergoferon in the Treatment of Acute Respiratory Viral Infections in Children
The international multicenter double-blind placebo-controlled randomized clinical study in parallel groups.The objective of this study is to obtain additional data on the efficacy and safety of Ergoferon in the treatment of acute…
- Trial name
- NCT03039621
- Testing
- Ergoferon
- Where
- 13 sites in Kazakhstan, Russia
- Volunteers
- 287 people
- Sponsor
- Materia Medica Holding
Influenza
A Phase 2a to Evaluate the Safety of MEDI8852 in Adults With Uncomplicated Influenza
The purpose of this study is to evaluate safety and tolerability of a single dose of MEDI8852 when given with oseltamivir, the safety and tolerability of oseltamivir alone, and the safety and tolerability of a single dose of…
- Trial name
- MEDI8852 (NCT02603952)
- Testing
- Oseltamivir, MEDI8852
- Where
- 31 sites in United States, South Africa
- Volunteers
- 126 people
- Sponsor
- MedImmune LLC